Cardiopulmonary Bypass clinical trials at UCSF

1 research study open to eligible people

Cardiopulmonary bypass is a technique that takes over the function of the heart and lungs during surgery. UCSF is running trials to see if a drug called ravulizumab can protect kidney patients from complications. These studies compare ravulizumab to a placebo to check its effectiveness.

Showing trials for

  • ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

    open to eligible people ages 18-90

    The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

    San Francisco, California and other locations

Last updated: